# EOLS catalysts: Evolus, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/eols/catalysts

> Evolus, Inc. (EOLS) has no upcoming catalysts in this calendar. The latest recorded is the Evolus, Inc. earnings report, November 4, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Evolus, Inc. |
| Ticker | EOLS (Nasdaq) |
| SEC CIK | 1570562 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/eols |

## Cash runway

Cash $41.7M as of 2026-09-30; quarterly burn $1.9M; about 64.7 months of runway at that rate (XBRL company facts, accession 0001628280-26-070250).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 15, 2018 | [Jeuveau (prabotulinumtoxina-xvfs) complete response letter (CRL)](https://sec-api.dev/pdufa/prabotulinumtoxina-xvfs) | EOLS |  | completed, complete response letter | "We have completed our review of this application, as amended, and ed our reasons for this cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22761085_2019_Orig1s000OtherActionLtrs.pdf%22)) |
| February 1, 2019 | [Jeuveau (prabotulinumtoxina-xvfs) FDA approval](https://sec-api.dev/pdufa/prabotulinumtoxina-xvfs) | EOLS |  | completed, approved | "BLA761085 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20190201, review_priority STANDARD; sponsor_name EVOLUS INC; product JEUVEAU (PRABOTULINUMTOXINA-XVFS)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761085%22)) |
| January 21, 2025 | [Evolus, Inc. earnings report](https://sec-api.dev/companies/eols/catalysts) | EOLS |  | completed | "The preliminary unaudited results described in this press release are based on the most current information available to management and are subject to change until the audit of the company's 2024 financial results is completed and the company reports its full financial results for the fourth quarter and full-year 2024, which is anticipated to occur in early March 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1570562/000157056225000006/ex991012125.htm)) |
| Feb 2025 | [Evolysse (evolysse) FDA approval](https://sec-api.dev/pdufa/evolysse) | EOLS |  | completed, approved | "In February 2025, we received approval from the U.S. Food and Drug Administration ("FDA") for Evolysse™ Form and Evolysse™ Smooth injectable HA gels for wrinkles and folds, such as nasolabial folds." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1570562/000162828026014001/eols-20251231.htm)) |
| February 13, 2025 | [Evolus, Inc. FDA approval](https://sec-api.dev/companies/eols/catalysts) | EOLS |  | completed, approved | "On February 13, 2025, the Company received FDA approval for EvolysseTM Form and EvolysseTM Smooth injectable hyaluronic acid gels for the treatment and improvement of moderate to severe nasolabial folds facial wrinkles." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1570562/000157056225000020/eols-20241231.htm)) |
| March 4, 2025 | [Evolus, Inc. earnings report](https://sec-api.dev/companies/eols/catalysts) | EOLS |  | completed | "Evolus Reports Record Fourth Quarter and Full Year 2024 Financial Results; Reaffirms 2025 Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1570562/000157056225000017/q42024eolsex991.htm)) |
| May 7, 2025 | [Evolus, Inc. earnings report](https://sec-api.dev/companies/eols/catalysts) | EOLS |  | completed | "Evolus Reports First Quarter 2025 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1570562/000157056225000074/q12025eolsex991.htm)) |
| August 1, 2025 | [Evolus, Inc. earnings report](https://sec-api.dev/companies/eols/catalysts) | EOLS |  | completed | "Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1570562/000157056225000094/q22025eolsex991.htm)) |
| November 5, 2025 | [Evolus, Inc. earnings report](https://sec-api.dev/companies/eols/catalysts) | EOLS |  | completed | "Evolus Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1570562/000162828025049564/q32025eolsex991.htm)) |
| January 9, 2026 | [Evolus, Inc. earnings report](https://sec-api.dev/companies/eols/catalysts) | EOLS |  | completed | "The preliminary unaudited results described in this press release are based on the most current information available to management and are subject to change until the audit of the company's 2025 financial results is completed and the company reports its full financial results for the fourth quarter and full-year 2025, which is anticipated to occur in early March 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1570562/000157056226000003/ex991010926.htm)) |
| March 3, 2026 | [Evolus, Inc. earnings report](https://sec-api.dev/companies/eols/catalysts) | EOLS |  | completed | "Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1570562/000162828026013872/q42025eolsex991.htm)) |
| May 4, 2026 | [Evolus, Inc. earnings report](https://sec-api.dev/companies/eols/catalysts) | EOLS |  | completed | "Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1570562/000157056226000064/q12026eolsex991.htm)) |
| August 5, 2026 | [Evolus, Inc. earnings report](https://sec-api.dev/companies/eols/catalysts) | EOLS |  | completed | "Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1570562/000162828026053384/q22026eolsex991.htm)) |
| November 4, 2026 | [Evolus, Inc. earnings report](https://sec-api.dev/companies/eols/catalysts) | EOLS |  | completed | "Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth; Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year 2026 Financial Outlook" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1570562/000162828026070150/q32026eolsex991.htm)) |

## Drugs

- [Evolysse (evolysse)](https://sec-api.dev/pdufa/evolysse): 
- [Jeuveau (prabotulinumtoxina-xvfs)](https://sec-api.dev/pdufa/prabotulinumtoxina-xvfs): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/eols/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "EOLS catalysts: Evolus, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/eols/catalysts

```bibtex
@misc{secapidev_companies_eols_catalysts_20261116,
  title        = {EOLS catalysts: Evolus, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/eols/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_eols_catalysts_20261116","title":"EOLS catalysts: Evolus, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/eols/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
